Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam

Table 2

Subclinical stages according to Kidney Disease Improving Global Outcomes (KDIGO) 2012 among HIV-infected patients in Soc Trang, Vietnam.

Variables	KDIGO 2012
	Stage 1; n = 229	Stage 2; n = 137	Stage 3a; n = 29	Stage 3b; n = 2	Stage 4; n = 3
Creatinine	70.1 ± 12.6	77.5 ± 13.7	97.2 ± 18.8	151.6 ± 51.5	167.9 ± 16.9	<0.01
eGFR	111.9 ± 18.1	80.3 ± 6.6	56.4 ± 3.7	40.7 ± 3.9	21.8 ± 5.5	<0.01
AST	41.6 ± 37.8	38.4 ± 27.2	34.4 ± 12.4	53.4 ± 12.8	71.6 ± 59.5	0.16
ALT	44.4 ± 42.2	37.9 ± 28.1	31.8 ± 17.3	74.2 ± 69.4	62.9 ± 33.1	0.14
Hb	13.6 ± 1.7	13.4 ± 1.6	13.4 ± 1.3	14.3 ± 0.7	12.5 ± 0.7	0.25
CD4 count	531.5 ± 233.8	530.7 ± 404.9	470.2 ± 251.2	526.5 ± 345.8	130.7 ± 24.4	0.02